Silicon is the second most abundant element in the Earth’s crust, yet it is present in only trace amounts in human tissues. Despite this modest abundance, silicon plays a remarkably specific biological role: it is required for the normal formation of collagen and for the mineralisation of bone, and silicon deficiency produces bone abnormalities that are distinct from and complementary to the bone loss seen with calcium, vitamin D, or vitamin K deficiency. The bone health community has focused almost exclusively on calcium and vitamin D for decades; the role of silicon in bone health is one of the most overlooked aspects of skeletal nutrition.
The Role of Silicon in Bone Matrix
Silicon is concentrated in areas of active bone formation — the growth plates, the periosteum (the membrane covering bone), and the osteoid (the protein matrix that mineralises to form bone). Studies in chick embryos showed that silicon deficiency produces bone abnormalities specifically in the regions where silicon is normally concentrated, suggesting a direct role in the biochemistry of bone matrix formation rather than a general metabolic effect. The proposed mechanism involves silicon’s interaction with the enzymes that synthesise collagen and with the proteins that organise the bone mineralisation process.
At the molecular level, silicon (as orthosilicic acid, the bioavailable form) appears to increase the activity of prolyl hydroxylase — the enzyme that hydroxylates proline residues in collagen, a required step in collagen triple helix formation. Without adequate silicon-dependent prolyl hydroxylation, collagen synthesis is impaired, and the bone matrix that is formed is structurally weaker than normal. This means that even with adequate calcium and vitamin D, bone that is silicon-deficient will have a suboptimal collagen matrix and will not mineralise properly.
Silicon and Connective Tissue Beyond Bone
Silicon’s role in collagen synthesis extends beyond bone to all connective tissues: skin, blood vessels, tendons, and cartilage. This is why silicon deficiency is also associated with skin ageing (reduced collagen in the dermis), weakened blood vessel walls (particularly the elastic fibres in arteries), and cartilage abnormalities. The clinical implication is that silicon supplementation may have benefits for skin elasticity and vascular health alongside its effects on bone — though these applications are less well studied than the bone health applications.
In skin health specifically, oral silicon supplementation (as methylsilanetriol, a bioavailable silicon form) at 10-20mg daily has been shown to improve skin elasticity, reduce brittleness of hair and nails, and increase the tensile strength of collagen in the dermis. These effects are consistent with the role of silicon as a cofactor in prolyl hydroxylase, which is equally important in skin collagen as in bone collagen.
Food Sources and Bioavailability
The richest food sources of silicon are whole grains (particularly oats, barley, and rice), bananas, beans, and to a lesser extent leafy vegetables and nuts. The silicon content of water varies significantly by region — some mineral waters are rich in orthosilicic acid, while others have negligible amounts. Beer is a surprisingly significant dietary source of silicon (approximately 20-30mg per litre), derived from the silicic acid in hops and barley husks — though the alcohol content complicates this as a therapeutic recommendation.
The most bioavailable supplemental form is orthosilicic acid (OSA), typically provided as methylsilanetriol or asstabilised OSA in solution. The evidence-based dose for bone health applications is 10-25mg of elemental silicon daily, from OSA or methylsilanetriol. This dose is achievable from food sources alone in people who consume large quantities of whole grains and bananas — but most Western diets fall well below this, making supplementation a reasonable consideration for anyone concerned about bone density.
Why Vitamin D and K2 Must Be Taken Together
Vitamin D increases calcium absorption from the gut, but without adequate vitamin K2, the calcium driven into circulation is directed toward soft tissue calcification rather than bone mineralisation. Vitamin K2 (specifically menaquinone-7, MK-7) activates osteocalcin and matrix Gla protein, which direct calcium into bone and prevent arterial calcification. Studies in post-menopausal women show that vitamin D3 combined with K2 (MK-7) improves bone mineral density more effectively than vitamin D3 alone.
The Magnesium Cofactor Requirement
Vitamin D activation requires magnesium as a cofactor at multiple steps. Without adequate magnesium, oral vitamin D supplementation produces less active vitamin D metabolite per unit dose. The three-way combination of vitamin D3, K2 (MK-7), and magnesium glycinate or citrate represents a rationally structured approach to bone health, where each component supports the activation of the others.
Leave a Reply